Edwards Lifesciences Corporation
NYSE:EW Rapport sur les actions
Capitalisation boursière : US$39.1b
Edwards Lifesciences Résultats passés
Passé contrôle des critères 4/6 Edwards Lifesciences a connu une croissance annuelle moyenne de ses bénéfices de 11.3%, tandis que le secteur Medical Equipment a vu ses bénéfices augmenter de en hausse à 13.2% par an. Les revenus ont augmenté de en hausse à un taux moyen de 7.8% par an. Le rendement des capitaux propres de Edwards Lifesciences est 16.3% et ses marges nettes sont de 24.8%.
Informations clés
11.3%
Taux de croissance des bénéfices
12.0%
Taux de croissance du BPA
Medical Equipment Croissance de l'industrie 8.9% Taux de croissance des recettes 7.8% Rendement des fonds propres 16.3% Marge nette 24.8% Dernière mise à jour des bénéfices 30 Sep 2024
Mises à jour récentes des performances passées
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Oct 25
Edwards Lifesciences Corporation to Report Q3, 2024 Results on Oct 24, 2024 Oct 17
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Jul 25
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 27
Edwards Lifesciences Corporation to Report Q1, 2024 Results on Apr 25, 2024 Apr 20
Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture Feb 21
Afficher toutes les mises à jour
Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW) Nov 11
Insider notifies of intention to sell stock Nov 07
Edwards Lifesciences Corporation Presents Data at TCT Reinforce Commitment to Structural Heart Innovation Nov 02
TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation Oct 30
Edwards Lifesciences Announces Results from the EARLY TAVR Trial Oct 29
Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts Oct 25
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Oct 25
Edwards Lifesciences Corporation Provides Earnings Guidance for the Fourth Quarter and Reiterates Sales Guidance for the Full Year 2024 Oct 25
Edwards Lifesciences Corporation to Report Q3, 2024 Results on Oct 24, 2024 Oct 17 Robbins Geller Rudman & Dowd LLP Updates on Class Action Lawsuit Against Edwards Lifesciences Corporation Oct 15
Insider exercised options and sold US$107k worth of stock Sep 19
Edwards Launches SAPIEN 3 With Alterra Prestent in Europe for Transcatheter Pulmonic Valve Implantation Sep 17
Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates Sep 11
Consensus revenue estimates decrease by 11% Sep 10 Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW). Sep 04
Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future Aug 30
Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)? Aug 17
Now 20% undervalued after recent price drop Aug 01
Investor sentiment deteriorates as stock falls 27% Jul 31
Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut Jul 26
Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW) Jul 26
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Jul 25 Edwards Lifesciences Corporation Provides Earnings Guidance for the Third Quarter of 2024
Edwards Lifesciences Corporation (NYSE:EW) agreed to acquire the remaining unknown majority stake in Innovalve Bio Medical Ltd. for $300 million. Jul 15
Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E Jul 12
Now 15% overvalued Jul 02
Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet? Jun 24
Edwards Lifesciences Corp Looks Bullish (Technical Analysis) Jun 22
Now 20% overvalued Jun 22
Edwards Lifesciences Announces Results from Analysis of Data from Partner Trials Examining Outcomes of Transcatheter Aortic Valve Replacement Patients with Small Annulus Jun 06
Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion. Jun 05
Corporate VP & CFO notifies of intention to sell stock May 23
Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future May 13
Insider notifies of intention to sell stock May 13
Edwards Lifesciences Corporation Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability May 09
Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade) May 09
Non-Executive Chairman of the Board exercised options and sold US$1.4m worth of stock May 03
When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)? Apr 29 Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 27
Edwards Lifesciences Corporation to Report Q1, 2024 Results on Apr 25, 2024 Apr 20
Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW) Apr 15
Edwards Lifesciences Announces the Release of Data from the Hudle Study Apr 09
Now 22% overvalued after recent price rise Apr 05
Corporate VP & CFO notifies of intention to sell stock Apr 03
Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear Apr 01
Edwards Lifesciences Corporation, Annual General Meeting, May 07, 2024 Mar 27
Edwards Lifesciences Announces Large, Real-World Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR Mar 12
Non-Executive Chairman of the Board exercised options and sold US$1.5m worth of stock Mar 05
Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture Feb 21
Insider notifies of intention to sell stock Feb 15
Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained) Feb 14
Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47 Feb 08
Full year 2023 earnings: Revenues and EPS in line with analyst expectations Feb 07
Edwards Lifesciences Corporation Provides Earnings Guidance for the First Quarter and Full Year 2024 Feb 07
Non-Executive Chairman of the Board exercised options and sold US$1.5m worth of stock Feb 07
Investor sentiment improves as stock rises 18% Feb 02
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve Feb 02
Edwards Lifesciences Corporation to Report Q4, 2023 Results on Feb 06, 2024 Jan 31
Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly Jan 28
The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing Jan 14
Edwards Lifesciences: Undervalued With A Substantial Upside Potential Jan 09
Corporate VP & CFO notifies of intention to sell stock Jan 01
Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up Dec 31
Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW) Dec 17
Non-Executive Chairman of the Board exercised options and sold US$1.1m worth of stock Dec 14
Edwards Lifesciences Corporation Reaffirms Earnings Guidance for the Year 2023 and Provides Earnings Guidance for the Full Year 2024 Dec 08
Edwards Lifesciences Corporation (NYSE:EW) announces an Equity Buyback for $1,000 million worth of its shares. Dec 07
Insider notifies of intention to sell stock Nov 16
Clasp IID One-Year Data Confirm Safety and Efficacy of Edwards Pascal System for Degenerative Mitral Regurgitation Oct 29
Third quarter 2023 earnings: EPS exceeds analyst expectations Oct 26
Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets Oct 26 Edwards Lifesciences Corporation Provides Earnings Guidance for Full Year 2023 and Fourth Quarter of 2023
Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet? Oct 23
Insider exercised options and sold US$214k worth of stock Oct 22
Edwards Lifesciences Corporation's Evoque Tricuspid Valve Replacement System Receives CE Mark Oct 20
Edwards Lifesciences Corporation to Report Q3, 2023 Results on Oct 25, 2023 Oct 19
Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)? Oct 09
Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value Sep 26
Insider notifies of intention to sell stock Sep 16
A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW) Sep 11
Corporate VP & CFO notifies of intention to sell stock Sep 03
Edwards Lifesciences: Rising Dominance In Structural Heart Disease Aug 21
Edwards Lifesciences Corporation Announces the Results of the Eu-Hyprotect Registry Aug 15
Non-Executive Chairman of the Board exercised options and sold US$1.3m worth of stock Aug 09
Insufficient new directors Aug 01
Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023 Jul 28
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Jul 28
Ventilation des recettes et des dépenses
Comment Edwards Lifesciences gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes NYSE:EW Recettes, dépenses et bénéfices (USD Millions ) Date Recettes Les revenus Dépenses G+A Dépenses de R&D 30 Sep 24 6,315 1,567 1,955 1,133 30 Jun 24 6,204 1,540 1,915 1,122 31 Mar 24 6,114 1,428 1,874 1,095 31 Dec 23 6,005 1,402 1,823 1,072 30 Sep 23 5,092 1,288 1,576 953 30 Jun 23 5,168 1,296 1,571 944 31 Mar 23 5,279 1,451 1,578 951 31 Dec 22 5,382 1,522 1,567 945 30 Sep 22 5,364 1,459 1,581 946 30 Jun 22 5,355 1,455 1,568 950 31 Mar 22 5,357 1,539 1,534 925 31 Dec 21 5,233 1,503 1,494 903 30 Sep 21 5,095 1,477 1,409 866 30 Jun 21 4,925 1,462 1,351 824 31 Mar 21 4,474 851 1,252 780 31 Dec 20 4,386 823 1,229 761 30 Sep 20 4,369 794 1,235 759 30 Jun 20 4,322 744 1,234 759 31 Mar 20 4,484 1,108 1,268 769 31 Dec 19 4,348 1,047 1,242 753 30 Sep 19 4,152 774 1,182 722 30 Jun 19 3,964 725 1,146 688 31 Mar 19 3,821 765 1,113 650 31 Dec 18 3,723 722 1,088 622 30 Sep 18 3,634 712 1,080 606 30 Jun 18 3,549 657 1,055 587 31 Mar 18 3,447 560 1,023 567 31 Dec 17 3,435 584 984 553 30 Sep 17 3,315 745 948 521 30 Jun 17 3,232 716 933 491 31 Mar 17 3,150 657 918 469 31 Dec 16 2,964 570 905 442 30 Sep 16 2,867 552 892 426 30 Jun 16 2,743 528 875 414 31 Mar 16 2,601 515 860 399 31 Dec 15 2,494 495 851 383 30 Sep 15 2,441 463 852 369 30 Jun 15 2,433 440 862 356 31 Mar 15 2,391 874 863 347 31 Dec 14 2,323 811 858 347 30 Sep 14 2,241 777 822 341 30 Jun 14 2,129 759 777 338 31 Mar 14 2,071 306 748 329 31 Dec 13 2,046 389 733 323
Des revenus de qualité: EW a des bénéfices de haute qualité .
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de EW sont inférieures à celles de l'année dernière EW. (24.8%) sont inférieures à celles de l'année dernière (25.3%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de EW ont augmenté de 11.3% par an au cours des 5 dernières années.
Accélération de la croissance: La croissance des bénéfices de EW au cours de l'année écoulée ( 21.7% ) dépasse sa moyenne sur 5 ans ( 11.3% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices EW au cours de l'année écoulée ( 21.7% ) a dépassé celle du secteur Medical Equipment 11.7%.
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de EW ( 16.3% ) est considéré comme faible .
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
